![Janet I. Swearson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Janet I. Swearson
Nessuna posizione attualmente
Storia della carriera di Janet I. Swearson
Precedenti posizioni note di Janet I. Swearson
Società | Posizione | Inizio | Fine |
---|---|---|---|
Threshold Pharmaceuticals, Inc.
![]() Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Direttore Finanziario/CFO | - | 31/08/2006 |
Receptor BioLogix, Inc.
![]() Receptor BioLogix, Inc. BiotechnologyHealth Technology Receptor BioLogix, Inc. provides receptor based biological therapeutics. It develops an intron fusion protein platform for the discovery of novel alternative forms splice variants of human proteins with therapeutic potential. The company was founded by H. Michael Shepard, John P. Adelman and Gail M. Clinton on May 27, 2003 and is headquartered in Mountain View, CA. | Direttore Finanziario/CFO | - | - |
Formazione di Janet I. Swearson
Santa Clara University | Masters Business Admin |
University of Minnesota | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Posizioni
Director of Finance/CFO | 2 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Settori
Health Technology | 3 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Threshold Pharmaceuticals, Inc.
![]() Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Receptor BioLogix, Inc.
![]() Receptor BioLogix, Inc. BiotechnologyHealth Technology Receptor BioLogix, Inc. provides receptor based biological therapeutics. It develops an intron fusion protein platform for the discovery of novel alternative forms splice variants of human proteins with therapeutic potential. The company was founded by H. Michael Shepard, John P. Adelman and Gail M. Clinton on May 27, 2003 and is headquartered in Mountain View, CA. | Health Technology |
- Borsa valori
- Insiders
- Janet I. Swearson
- Esperienza